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Abstract
Objectives Although there aremany reports about risk factors for
the development of BP-associated osteonecrosis of the jaws, the
role of dental implants as a local risk factor is still discussed,
especially in patients with oral BP treatment. Until now, a few
case reports and surveys display a possible minor risk in patients
with oral BP therapy,whereas the avoidance of implant placement
is generally accepted in patients with intravenous BP therapy.
Patient and methods In this study, the cases of 14 patients
with osteonecrosis of the jaws in association with BP ther-
apy and dental implant placement were analyzed carefully
with a detailed literature review.
Results Of 14 patients, nine had underlyingmalignant disease
and five patients had osteoporosis. In ten patients, implants
were placed either in the posterior mandible or maxilla; the
mean interval between implant insertion and disease onset
was 20.9 months. Pain (n12) and signs of infection (n10) were
the most common symptoms. Histologically, signs of infec-
tion were found in nine of 11 analyzed patients with presence
of Actinomyces in six patients. Two patients turned out to have
infiltration of underlying malignant disease.
Conclusions Posteriorly placed implants seem to be of
higher risk of development of osteonecrosis of the jaws.
Not only the implant placement but also the inserted implant
itself seems to be a continuous risk factor.
Clinical relevance The herein elaborated risk factors help den-
tists plan dental rehabilitation with implants in this high-risk
group of patients and indicate careful and regular dental recall.
Keywords Bisphosphonate-associated osteonecrosis of the
jaws (BRONJ) . Dental implants . Risk factors . Posterior
jaw . Infection
Introduction
About 100 years ago, phosphorus necrosis of the jaw was a
common disease in match factory workers. In 2003,Marx et al.
discovered an apparently similar type of osteopathology asso-
ciated with bisphosphonate (BP) medication [1]. Since then,
much has been published about “bisphosphonate-associated
osteonecrosis of the jaw” (BRONJ) [2–4]. Because BRONJ
is a major concern for patients and there is no remodeling
tendency in the affected bone, BP medication became a new
and important risk issue for dentists in general daily practice.
Many efforts have been made to prevent this localized bone
disease [5, 6]. Thus, many guidelines and prevention protocols
have been developed to guide the dental treatment of patients
before and during BP medication [7, 8]. The occurrence of
BRONJ seems to be intimately connected with local risk
factors; thus, elective invasive treatment (e.g., in dental implant
placement) seems to be a high-risk procedure and is strongly
advised against in various guidelines [9–11].
However, closer examination of the published data
reveals a lack of information concerning dental implants
and BRONJ. Several case reports and series have evaluated
implant failures in patients, primarily those receiving intra-
venous BP therapy. Other cohort studies showed minor risks
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of osteopathology development in patients receiving oral BP
therapy and dental implant insertion. On the other hand, the
local and short-term use of BP has been shown to have a
positive influence on osseointegration of all implants, dental
or otherwise [12, 13].
To date, guidelines concerning implant placement in
patients receiving BP therapy are ambiguous. Intravenous
BP therapy for underlying malignant disease seems to be a
clear contraindication for the placement of dental implants,
whereas implants can be placed in patients receiving oral
or intravenous BP for the treatment of osteoporosis. Nev-
ertheless, dentists are still uncertain whether, where, when,
how and in which patients it is possible to place dental
implants without a significant risk for the development of
BRONJ.
In this study, 14 patients with osteopathology of the jaw
associated with BP therapy and dental implant insertion
were analyzed carefully. A detailed literature review was
also conducted. We clarified the risk factors for implant
placement in patients receiving BP therapy to help dentists
distinguish high- and low-risk situations.
Patients and methods
The study sample included patients with BRONJ who were
evaluated, treated and followed up in a special outpatient
clinic at the Department of Craniomaxillofacial Surgery,
University Hospital of Zurich between 2005 and 2010.
During this period, 110 patients with osteopathology of the
jaw were referred to the clinic. For all patients, a detailed
medical history including underlying diseases, general risk
factors, medications, other therapeutic measures performed,
dental history and possible local risk factors was collected.
Additionally, a meticulous clinical examination was
performed.
In total, 14 (11 women, three men) of the 110 patients
were referred due to osteopathology of the jaw associated
with BP therapy and dental implants. Of these, nine patients
were treated with intravenous BP for malignant diseases and
five patients received BP therapy for the treatment of oste-
oporosis. Of the nine patients with underlying malignant
diseases, two had multiple myeloma, five had breast cancer,
one had prostate cancer and one patient had lung cancer. The
nine patients all received zoledronic acid (Zometa; Novartis,
Basel, Switzerland) and one had previously received
pamidronate (Aredia; Novartis).
The other five patients had no underlying malignant
disease, but osteoporosis was the indication for BP treat-
ment. Two of these patients received oral alendronate (Fosa-
max; Merck, Sharp, & Dohme GmbH, Munich, Germany)
therapy, one patient received intravenous ibandronate (Bon-
viva; Roche Pharma AG, Basel, Switzerland) therapy, and
two received pamidronate (Aredia; Novartis) therapy in a 3-
month regimen.
All implants in this study were conventional dental
screwed implants without modification. Because all
implants were inserted from different practitioners and
patients were referred with apparent osteopathology, data
about type of implant and manufacturer were not available
in all cases. Therefore, this information was not collected
and analyzed in this study.
To summarize the location of implant placement, all
implants placed in or posterior to the second premolar region
of the mandible or maxilla were defined as posterior implants
and all implants placed in or anterior to the first mandibular or
maxillary premolar were defined as anterior implants.
Cross-sectional imaging of both jaws was performed to
confirm the diagnosis and to visualize the dimensions of the
affected bone. A histological analysis was also performed to
confirm the diagnosis and exclude other bone lesions, espe-
cially the metastasis of underlying diseases.
During diagnosis and treatment, the infiltration of malig-
nant underlying disease was found in two patients: one
female patient with breast cancer (posterior mandible) and
one male patient with multiple myeloma (anterior mandi-
ble). Interestingly, the clinical and radiological presentations
of these patients resembled classical BRONJ. The other 12
patients had BRONJ in association with previous dental
implant placement.
To treat osteopathology, when general health status and
patient approval allowed, BP therapy was stopped 3–
6 months before surgical treatment to encourage bone
remodeling and necrotic bone sequestration. Surgical inter-
vention was then performed to remove the infected necrotic
bone and to allow soft-tissue healing. Additionally, systemic
anti-infectious treatment with antibiotics (mean: 4 weeks)
was performed.
All specimens were primarily obtained for medical pur-
poses, with the informed consent of the patients. The study
design fulfills the guidelines of the Declaration of Helsinki
regarding ethical principles for medical research involving
human subjects.
Literature review
The literature database PubMed, Embase and Ovid were
searched for “osteonecrosis of the jaw” in combination with
one of the following terms “bisphosphonate,” “dental
implants,” “local risk factors” and “implant insertion” using
the Boolean operator AND, in title, abstract and MeSH
terms. The search included articles published between
1995 and 2011. In total, 50 articles were identified (refer-
ences are available on request from the corresponding au-
thor). Two of these publications were excluded because they
were written in foreign languages not understandable for the
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authors. During the assessment process, 17 articles were
excluded because they described animal and clinical studies
in which BP treatment was performed to improve osseointe-
gration of dental implants without a link to BP-related
osteonecrosis of the jaws, and three other articles gave a
general overview about BRONJ without a focus on dental
implants as a local factor. Of those, 21 articles were exclud-
ed because they were either written in a language other than
English, French or German or they did not refer to the topic
of dental implant placement in patients with BP therapy. In
total, 17 articles were excluded because they described cases
or studies in which the application of bisphophonates was
used to improve osseointegration of dental implant.
All publications identified in the literature searches were
retrieved from online journals and selected on the basis of
the inclusion criteria. The selected papers were assessed
according to the following criteria for this study,
1. Study patients with BRONJ in association with dental
implants.
2. Number of patients with BRONJ in association with
dental implant placement.
3. Type of BP reported.
4. Underlying diseases of patients reported.
5. Location of BRONJ and thereof placed dental implants.
6. Symptoms and clinical picture.
Results
Fourteen patients had osteopathology of the jaw associated
with BP therapy in an area of previous dental implant
placement; in two patients, we found infiltration of the
underlying disease. The average duration of BP therapy
before the onset of jaw problems was 38 months in the
seven patients receiving intravenous BP therapy for under-
lying malignant diseases and about 50 months in the five
patients receiving BP treatment for osteoporosis. One fe-
male patient with osteoporosis did not know the exact
treatment duration but indicated that she had received BP
treatment for more than 5 years.
The medical information and BP treatment of these
patients is summarized in Table 1. In total, 23 dental
implants were inserted in 12 BRONJ patients.
BRONJ localization
Osteopathology developed in the mandible in eight patients
and in the maxilla in four patients. Nine patients received
posterior implants: four patients received five implants in
the posterior maxilla and five patients received six implants
in the posterior mandible. In three patients, 12 implants were
inserted in the anterior mandible. No patient with an osteo-
pathology received an implant in the anterior maxilla
(Fig. 1).
Implant history
Nine patients were referred by dentists due to peri-implant
problems or exposed bone around previously inserted
implants. In one male patient, two dental implants had been
explanted by the dentist after disturbed soft-tissue healing
and two new implants were inserted in the same area; heal-
ing disturbance persisted. In one female patient, massive
Table 1 Overview of patients with type of underlying disease, type of bisphosphonate medication, pathology report and presence of Actinomyces
Number Diagnosis BP Localization Histology (additional finding to necrotic bone) Actinomyces
1 MC Z Mandible Purulent osteomyelitis 1
2 O A–P Maxilla No biopsy No biopsy
3 MM P–Z Mandible Acute purulent osteomyelitis 1
4 O P Mandible Acute and chronic osteomyelitis –
5 PC Z Mandible Destructing purulent osteomyelitis fibrinoleucocytic exudate –
6 MC Z Maxilla Acute and chronic inflammation, suspicion on infiltration of multiple myeloma 1
7 MM Z Mandible –
8 MC Z Mandible Purulent osteomyelitis 1
9 MC Z Mandible Acute inflammation 1
10 MC Z Mandible Subepithelial infiltration of carcinoma –
11 O I Mandible Chronic inflammation –
12 Lca Z Maxilla Active inflammation 1
13 O A Mandible No biopsy No biopsy
14 O A Mandible
MC mamma carcinoma, MM multiple myeloma, O osteoporosis, PC prostate cancer, Lca lung carcinoma, Z zoledronic acid, P pamidronate, A
alendronate, I Ibandronate
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infection resulted from a sinus lift and dental implant inser-
tion; another female patient presented with massive con-
comitant osteopathology of the jaws following the
explantation of four interforaminal dental implants.
The mean interval between implant insertion and disease
onset was 20.9 months. In patients with malignant underly-
ing disease, the average interval was 17 months; in patients
with osteoporosis, it was 25.6 months. Detailed information
about the date of implant insertion was missing in one
patient, and the two patients with malignant histology were
excluded from this analysis.
Clinical presentation
Ten patients presented with pain. In nine patients, pus dis-
charge could be observed; six patients presented with a
submandibular or submental abscess. Four patients had par-
esthesia of the mandibular or infraorbital nerve. Eight
patients presented with exposed bone and lack of healing.
In four patients, a fistula was found; one extraoral fistula
was present in the submental area. Two patients presented
with involvement of the maxillary sinus. The male patient
with multiple myeloma infiltration presented with a sub-
mental abscess, and the female patient with breast cancer
metastasis presented with hard, yellowish, exposed bone in
the posterior mandible.
Diagnostic measures
Cone beam or thin-layer computed tomography (CT) was
performed to analyze volume expansion of the pathological
bone structure. In five patients, magnetic resonance imaging
(MRI) was also performed. All patients presented typical
radiological signs of BP-associated osteopathology includ-
ing thickening of the bone, massive sclerosis, poor cortico-
medullary differentiation and periosteal new bone formation
(Fig. 2a–c). The two patients with infiltration of underlying
malignant diseases showed the same radiological signs. No
clear sign of infiltration or metastasis could be found in the
radiological images (Fig. 3a, b).
Histological analysis
Bone specimens were obtained from 12 patients for histo-
logical analysis during surgical therapy or from a bone
biopsy. Affected bone was available for histological analysis
from all nine patients with underlying malignant disease.
Necrotic bone was found in samples from all 12 patients.
Metastasis or infiltration of the underlying disease with
concomitant inflammation was also found in specimens
from two patients. The bone specimens of the other ten
patients showed typical histological findings of inflamma-
tion in association with BP-associated osteopathology. Acti-
nomyces plaques were found in samples from seven patients
(Table 1 and Fig. 4). Two patients with osteoporosis refused
Fig. 1 Display of localization of bisphosphonate-associated osteonec-
rosis of the jaw in 12 patients with dental implants as the local factor.
The two patients with malignant histology were excluded from this
figure
Fig. 2 a Coronal view of one female patient with previous implant
insertion, sinus lift and oral bisphosphonate therapy. A sequester and
sclerotiv changes of the lateral wall of the maxillary sinus are visible. b
The same patient. Sagittal view of the cone beam tomography of the
right side shows sclerotic changes of the maxillary sinus walls with
concomitant sinusitis. c Sagittal view of the left side of the maxilla
shows no changes of the bone with well osseointegrated dental
implants
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to provide samples for histological analysis of the affected
bone.
Treatment
Surgical treatment involving the removal of necrotic bone
was performed in ten of the 12 patients (Fig. 5). Two female
patients refused surgical treatment. Complete remission was
accomplished in nine of ten surgically treated patients
(Fig. 6). One surgically treated female patient died during
follow-up due to underlying diseases. All patients received
additional anti-infectious treatment with antibiotics. In all
patients, pain and hypesthesia symptoms improved during
anti-infectious treatment.
The male patient with multiple myeloma infiltration was
surgically treated with implant explantation, decortication
and revision of the abscessed area. He also received chemo-
therapy for multiple myeloma progression. Complete remis-
sion of the infected jaw bone was accomplished. The female
patient with breast cancer infiltration was treated conserva-
tively due to her poor general condition. She died during
follow-up.
Literature analysis
In total, 28 articles were included in the literature review,
most of them were case reports or series (n15). The other
articles were literature reviews, and only two articles were
surveys or studies. Table 2 presents the numbers and per-
centages of the papers meeting the different criteria.
Of the 28 included articles, only five presented patients
with apparent diagnosis of BRONJ, thereof four case reports
and one case series. In total, four original articles and
Fig. 3 a Axial view of a cone beam tomography of a male patient with
submental abscess. The lingual aspect of the frontal mandibular bone
shows signs of a sequestrum with surrounding sclerotic areas. b Sag-
ittal view of the same patient shows periosteal reaction in the lingual
area and massive submental swelling. However, histologically, the
patient showed infiltration of multiple myeloma
Fig. 4 Histological depiction of removed bone. Central Actinomyces
plaque (“Druse” surrounded by neutrophilic granulocytes, adjacent to
necrotic bone (asterisk). Insert magnification of fusiform Actinomyces
bacteria (modified Gram − stain). H&E stain of specimen of the same
patient as Figs. 5 and 6
Fig. 5 Intraoperative view of an area of osteonecrosis of the jaws in
association with bisphosphonate therapy and dental implant insertion
as a local factor. The implant surrounding necrotic bone area shows
signs of infection
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surveys reported about implant failure in patients with oral
BP therapy, but a verified diagnosis of BRONJ has not been
performed. In total, nine articles were about patients with
either BRONJ in association with dental implants as a local
factor or implant failure in patients with BP medication
[14–22].
Thereof, in total, 31 patients with a total of 35 implants
showed osteonecrosis due to BP treatment and dental im-
plant placement. An analysis about the location of failed
implants showed that in patients with clear diagnosis of
BRONJ, eight implants have been placed in the posterior
maxilla, three in the anterior maxilla, 19 in the posterior
mandible and five in the anterior mandible. Of the total 35
implants, 77 % (n27) have been placed in the posterior jaw,
whereas only 23 % (n8) have been placed in the anterior jaw
area. Two studies gave information about the location of
failed implants in patients with BP medication but without
the clear diagnosis of BRONJ. However, location was not
analyzed due to the lack of information about the presence
of BRONJ. All patients with BRONJ and implant failure
showed clinical symptoms and signs of infection (peri-
implantitis) as the first sign.
The underlying disease was osteoporosis in 15 patients,
multiple myeloma in seven patients, breast cancer in seven
patients and prostate carcinoma in two patients. However,
15 patients were treated with oral BPs and 16 patients with
high potent intravenous BPs.
All patients in the published articles about implant failure
in association with BP therapy had osteoporosis as the
underlying disease, except 16 patients in the case series of
Lazarovici et al. [18] with underlying malignant disease.
Discussion
Seven years after the detection of the possible risk of BP
treatment on the jaw, it remains unclear whether BP treat-
ment should be an exclusion criterion for dental implant
insertion. Specifically, it remains unclear whether the inser-
tion of dental implants should be avoided only in patients
receiving intravenous BP therapy or if patients with osteo-
porosis receiving oral BP treatment are also at a higher risk
for osteopathology of the jaw [14]. In this study, 14 patients
with clinically apparent osteopathology of the jaws in asso-
ciation with BP therapy and dental implant placement were
analyzed. The two key findings of this study were first, the
predominant location of affected implants in the posterior
jaw area and second, that the clinical, and also the histolog-
ical, picture showed severe signs of infection in all exam-
ined cases. About a third of these patients had osteoporosis
as the underlying disease.
A few retrospective case series or cohort studies have
examined the incidence of osteopathology associated with
BP therapy and implant insertion [15, 19, 28, 31, 33]. In
2010, Koka et al. published a retrospective review that
examined implant survival in 55 postmenopausal women
who received oral BP therapy in comparison with a control
group of 82 women who did not receive BP therapy [33]. Of
the 121 implants, 120 survived in the BP user group, with
no patient presenting with osteonecrosis of the jaw. Among
those who did not use BP, 163 of 166 implants survived.
These authors suggested that implant therapy in BP users
was a “safe and predictable” procedure that did not require a
drug holiday. However, their follow-up period was short,
and their sample size was relatively small [33]. Other studies
have also examined the development of ONJ after the in-
sertion of dental implants, with the same results [15, 27, 28].
However, Goss et al. published another interesting find-
ing in their south Australian case series in 2010. They
Fig. 6 Complete remission 6 weeks after surgical revision of the left
posterior maxilla (the same patient as Fig. 5)
Table 2 Display of number and type of previous published articles of
bisphosphonate-associated osteonecrosis of the jaws due to implant
therapy
Articles n 50
Excluded 22
Publication in Dutch or Italian 2
Osseointegration-studies with bisphosphonates 17
General overview about BRONJ 3
Included 28
Case report [13, 15, 19–25] 8
About patients with BRONJ 4
About failed implants in patients with BP 1
About successful implant insertion in patients with BP 3
Case series[14, 17, 26–30] 6
About patients with BRONJ 1
About successful implant insertion in patients with BP 5
Original article (case control study)[31, 32] 2
Survey [16, 18] 2
Literature review [16, 18, 33–42] 10
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collected data using a mail-administered questionnaire and
calculated the rate of implant failure on the basis of the
assumption that 5 % of the population took BP [17]. They
calculated a failure rate of 0.89 % and mentioned that there
is a “certain amount of risk” for patients taking oral BP. In
their study, seven implants failed in patients receiving oral
BP treatment. Interestingly, implants had integrated success-
fully in four of those patients before the initiation of BP
therapy. This finding indicates that not only the surgical
insertion of the implant, but also the implant itself, is a local
risk factor for BP-associated osteopathology [17]. In this
study, the average time between implant insertion and the
diagnosis of osteopathology of the jaw was 20.9 months.
Implant insertion thus appeared not to be the only factor
contributing to the etiology of the osteopathology. Before
the appearance of the problem, typically as infection or
exposed bone and threads, the inserted implants seemed to
clinically osseointegrate well.
Lazarovici et al. [18] published similar findings in a case
series of 27 patients with osteopathology of the jaw in
association with dental implant placement and BP. In their
study, implant insertion was a local factor in 18.6 % (n027)
of 145 osteopathology patients. Eleven (41 %) of these
patients were on oral BP treatment and 17 received intrave-
nous BP treatment. Most (77.8 %) patients in their study
developed clinical evidence of osteopathology more than
6 months after implant placement. Osteopathology after
intravenous BP treatment occurred earlier, relative to im-
plant insertion, than ONJ after treatment with oral BP. In
four of 27 patients with osteopathology of the jaw, implant
insertion was performed an average of 80 months before the
start of BP therapy; thus, in those patients, the implant itself,
and not the surgical insertion, seemed to be the local factor
affecting the development of osteonecrosis.
Similar findings can be seen in the 12 patients presented
here. The average interval between implant placement and
clinical evidence of BRONJ was 21 months. The interval
was longer in patients receiving BP treatment for osteopo-
rosis (26 months) than in patients receiving intravenous BP
therapy for underlying malignant disease (17 months), sim-
ilar to the findings of Lazarovici et al. Only one patient
developed clinical evidence promptly (2 months) after im-
plant insertion.
Some other aspects were conspicuous. In this study, nine
of 12 patients showed implant failure in the posterior max-
illa or mandible, whereas only three had implant failure in
the anterior jaw. Nineteen of 27 implants in the Lazarovici et
al. study were placed in the posterior maxilla or mandible.
One important risk factor may thus be implant location.
Dental implants placed in the posterior region of the man-
dible or maxilla seem to be at a higher risk of development
of osteopathology of the jaw than implants inserted in the
anterior region. Martin et al. [19] published a cohort study of
8,572 patients. Of these, 16 patients had ONJ related to BP
therapy and dental implant insertion. In total, 44 implants
failed: 15 in the posterior maxilla, 17 in the posterior man-
dible and six each in the anterior maxilla and mandible.
Other studies have reported findings consistent with these
results; three-fourths of implants of the to-date published
cases of BRONJ in association with implant insertion were
placed in the posterior jaw [14, 16, 20]. The influence of
implant location may as well explain the low rates of osteo-
pathology found in some other studies such as that of
Shabestari et al. [31]. They analyzed 21 female patients with
osteoporosis who received oral BP therapy after the place-
ment of 46 dental implants and found no case of BRONJ. In
addition to the relatively small sample sizes, 32 of the 46
implants were placed in the anterior mandible or maxilla;
only 14 were placed in the posterior mandible or maxilla.
The etiopathological process of BRONJ remains unclear.
However, a strong connection with infection seemed evident
in these patients [43, 44]. Acute and chronic inflammation
with verification of Actinomyces, in addition to nonvital
bone, was found in all patients who were analyzed histolog-
ically in this study. After starting systemic anti-infectious
treatment, discomfort and other symptoms such as hypoes-
thesia resolved in all patients. The analysis of the literature
showed the same result. All patients with BRONJ associated
with dental implants had symptoms and signs of infection,
for example, pus discharge [14, 16, 19]. For example, Favia
et al. [16] reported a histological analysis of osteopathology
of a 65-year-old multiple myeloma patient with implant
failure in the posterior mandible. The apical area of the
implant exhibited signs of osseointegration, but osteoblasts
and signs of remodeling were absent. In other surface areas,
dense connective tissue with inflammatory cells could be
seen [16].
That the risk of osteopathology development in the pos-
terior jaw is higher and that the development of osteopathol-
ogy is not necessarily associated chronologically with
implant insertion could be consistent with this conclusion.
Because posterior dental implants are difficult for patients to
clean, the development of peri-implant problems such as
peri-implantitis followed by osteopathology of the jaw is
more likely.
Another important side issue is the value of histological
analysis of the affected bone. Both patients with malignant
infiltration of affected bone in this study showed clinical and
radiological signs characteristic of BRONJ, rather than signs
of underlying disease infiltration. Only the histological anal-
ysis showed the infiltration of malignant cells. Thus, histo-
logical analysis of BRONJ-suspicious lesions in patients
with underlying malignant disease remains of the utmost
importance. The number of patients in this study is low;
however, until now, evidence-based data about patients with
BRONJ in association with BP treatment is still missing.
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Conclusions
Several conclusions can be reached from this study.
Implant- and BP-associated osteopathology of the jaw
occurs in patients receiving oral BP therapy for osteoporosis
and can be devastating. Implant insertion in the posterior
jaw seems to increase the risk for the BP-associated devel-
opment of osteopathology of the jaw; most reported cases of
BRONJ and dental implants occur in the posterior jaw. This
factor should be thoroughly considered before implant
placement in patients receiving long-term oral BP treatment.
Not only the surgical insertion of a dental implant, but
also the inserted implant itself (particularly the peri-implant
“danger zone”), appears to be a continuous risk factor for
the development of osteopathology. Thus, in patients receiv-
ing oral or intravenous BP therapy for osteoporosis, implant
placement must be calculated and planned carefully, with
special emphasis on the location of the implants, compliance
and manual abilities of the patient. Furthermore, careful and
frequent follow-up of patients with dental implants receiv-
ing BP therapy is strongly recommended.
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